UK regulator signs off third COVID-19 vaccine, this one from Moderna

8 January 2021

The COVID-19 vaccine developed by US biotech Moderna (Nasdaq: MRNA) has today been given regulatory approval for emergency supply by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

This follows a thorough and rigorous assessment by the MHRA’s teams of scientists, including advice from the independent Commission on Human Medicines, which reviewed in depth all the data to ensure this vaccine meets the required standards of safety, quality and effectiveness, the Agency stressed.

This is the third COVID-19 vaccine to be approved for use by the MHRA and is the second mRNA vaccine. This follows clearance of BNT162b2 (now trade-named Comirnaty), the vaccine from USA-based Pfizer (NYSE: PFE) and German firm BioNTech (Nasdaq: BNTX). The Agency has also approved use of the AstraZeneca (LSE: AZN)/Oxford University vaccine.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK